Literature DB >> 11697323

Long-term results of irradiation for patients with progressive Graves' ophthalmopathy.

S D Marquez1, B L Lum, I R McDougall, S Katkuri, P S Levin, M MacManus, S S Donaldson.   

Abstract

PURPOSE: To determine the long-term outcome of radiotherapy (RT) in patients with progressively symptomatic thyroid eye disease and to evaluate the potential long-term sequelae. METHODS AND MATERIALS: Four hundred fifty-three patients provided written informed consent and received retrobulbar RT for Graves' ophthalmopathy at Stanford University Medical Center; 197 with 1 year of follow-up were retrospectively analyzed. Of the 197 patients, 189 received RT to the bilateral retrobulbar regions, and 4 received unilateral RT. The technical information was unavailable for 4 patients. Patients were assessed by chart review, telephone interview, questionnaire, and multidisciplinary physician examination. Eye impairment was scored using the SPECS system. The end point review included the before and after treatment SPECS score, surgical intervention, and patient satisfaction. Potential complications, including cataract development, retinopathy, and tumor formation, were investigated. Multivariate analyses were performed to assess the prognostic variables.
RESULTS: Improvement or resolution was 89% for soft-tissue findings; 70% for proptosis; 85% for extraocular muscle dysfunction; 96% for corneal abnormalities; and 67% for sight loss. The response to RT may take >6 months to stabilize. Factors predictive of response varied in the individual SPECS categories but included the initial SPECS score, pretreatment thyroid status, female gender, a 20-Gy RT dose, and a history of hypertension. Nonpredictive factors included a history of tobacco use, diabetes mellitus, steroids, and prior cataracts. Only 16% required surgical intervention to preserve their vision or restore binocular vision. Twenty-two patients (12%) developed cataracts after irradiation (median 11 years). No patient developed a tumor within the RT field during the follow-up period (range 1-29 years). Ninety-eight percent of patients were pleased with their results, and 2% believed their symptoms progressed despite RT.
CONCLUSIONS: Retrobulbar irradiation (20 Gy) is safe and effective treatment for progressive Graves' ophthalmopathy, with a 96% overall response rate, 98% patient satisfaction rate, and no irreparable long-term sequelae, with follow-up extending 29 years. The most common late effect observed was cataract development, which occurred more frequently in older patients and was reversible with extraction. Elective surgical intervention after RT should be withheld until patients have demonstrated a plateau in response.

Entities:  

Mesh:

Year:  2001        PMID: 11697323     DOI: 10.1016/s0360-3016(01)01699-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  24 in total

Review 1.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

2.  Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study.

Authors:  Yujie Wu; Boding Tong; Yongheng Luo; Guiyuan Xie; Wei Xiong
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.

Authors:  E Sisti; F Menconi; M Leo; M A Profilo; T Mautone; B Mazzi; R Rocchi; F Latrofa; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-01-18       Impact factor: 4.256

4.  Feasibility of tomotherapy for Graves' ophthalmopathy: Dosimetry comparison with conventional radiotherapy.

Authors:  Nam P Nguyen; Shane P Krafft; Paul Vos; Vincent Vinh-Hung; Misty Ceizyk; Siyoung Jang; Anand Desai; Dave Abraham; Lars Ewell; Christopher Watchman; Russ Hamilton; Beng-Hoey Jo; Ulf Karlsson; Lexie Smith-Raymond
Journal:  Strahlenther Onkol       Date:  2011-06-28       Impact factor: 3.621

5.  Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids?

Authors:  P Grassi; D Strianese; R Piscopo; R Pacelli; G Bonavolontà
Journal:  Ir J Med Sci       Date:  2017-01-03       Impact factor: 1.568

Review 6.  Thyroid eye disease: towards an evidence base for treatment in the 21st century.

Authors:  Erin F Gillespie; Terry J Smith; Raymond S Douglas
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

7.  Orbital radiotherapy for Graves' ophthalmopathy: useful or useless? Safe or dangerous?

Authors:  L Bartalena; C Marcocci; C A Gorman; W M Wiersinga; A Pinchera
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

8.  Radiotherapy in the treatment of Graves ophthalmopathy-to do it or not?

Authors:  Aneta Zygulska
Journal:  J Ocul Biol Dis Infor       Date:  2009-10-06

9.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

10.  Update on thyroid eye disease and management.

Authors:  Erick D Bothun; Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.